Literature DB >> 17828818

Hepatitis C virus infection and apoptosis.

Richard Fischer1, Thomas Baumert, Hubert-E Blum.   

Abstract

Apoptosis is central for the control and elimination of viral infections. In chronic hepatitis C virus (HCV) infection, enhanced hepatocyte apoptosis and upregulation of the death inducing ligands CD95/Fas, TRAIL and TNFalpha occur. Nevertheless, HCV infection persists in the majority of patients. The impact of apoptosis in chronic HCV infection is not well understood. It may be harmful by triggering liver fibrosis, or essential in interferon (IFN) induced HCV elimination. For virtually all HCV proteins, pro- and anti-apoptotic effects have been described, especially for the core and NS5A protein. To date, it is not known which HCV protein affects apoptosis in vivo and whether the infectious virions act pro- or anti-apoptotic. With the availability of an infectious tissue culture system, we now can address pathophysiologically relevant issues. This review focuses on the effect of HCV infection and different HCV proteins on apoptosis and of the corresponding signaling cascades.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828818      PMCID: PMC4611765          DOI: 10.3748/wjg.v13.i36.4865

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  106 in total

Review 1.  An apoptosis biomarker goes to the HCV clinic.

Authors:  Ariel E Feldstein; Gregory J Gores
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

2.  HCV E2 may induce apoptosis of Huh-7 cells via a mitochondrial-related caspase pathway.

Authors:  Hui-Ling Chiou; Yih-Shou Hsieh; Ming-Ru Hsieh; Tzy-Yen Chen
Journal:  Biochem Biophys Res Commun       Date:  2006-05-02       Impact factor: 3.575

3.  Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.

Authors:  N Zhu; A Khoshnan; R Schneider; M Matsumoto; G Dennert; C Ware; M M Lai
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  The expression of Fas and Fas ligand, and the effects of interferon in chronic liver diseases with hepatitis C virus.

Authors:  Kazuo Yoneyama; Takashi Goto; Kouichi Miura; Ken ichirou Mikami; Shigetoshi Ohshima; Kunio Nakane; Jiun Guey Lin; Masashiro Sugawara; Norio Nakamura; Kamon Shirakawa; Masafumi Komatsu; Sumio Watanabe
Journal:  Hepatol Res       Date:  2002-12       Impact factor: 4.288

5.  IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression.

Authors:  L M Sedger; D M Shows; R A Blanton; J J Peschon; R G Goodwin; D Cosman; S R Wiley
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

6.  Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N-terminal kinase-dependent manner.

Authors:  Dirk Graf; Anna Kordelia Kurz; Richard Fischer; Roland Reinehr; Dieter Häussinger
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

7.  Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells.

Authors:  R Fischer; M Schmitt; J G Bode; D Häussinger
Journal:  Gastroenterology       Date:  2001-04       Impact factor: 22.682

8.  Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity.

Authors:  H Zylberberg; A C Rimaniol; S Pol; A Masson; D De Groote; P Berthelot; J F Bach; C Bréchot; F Zavala
Journal:  J Hepatol       Date:  1999-02       Impact factor: 25.083

9.  Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C.

Authors:  Nicoletta Pelli; Francesco Torre; Andrea Delfino; Monica Basso; Antonino Picciotto
Journal:  J Interferon Cytokine Res       Date:  2006-02       Impact factor: 2.607

10.  Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction.

Authors:  Christel Gremion; Benno Grabscheid; Benno Wölk; Darius Moradpour; Jürg Reichen; Werner Pichler; Andreas Cerny
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more
  54 in total

1.  Soluble TRAIL levels decreased in chronic hepatitis C treatment with pegylated interferon α plus ribavirin: association with viral responses.

Authors:  Derya Seyman; Arzu Didem Yalcin; Nefise Oztoprak; Gizem Esra Genc; Nevgun Sepin Ozen; Filiz Kizilates; Hande Berk; Saadet Gumuslu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Role of apoptotic hepatocytes in HCV dissemination: regulation by acetaldehyde.

Authors:  Murali Ganesan; Sathish Kumar Natarajan; Jinjin Zhang; Justin L Mott; Larisa I Poluektova; Benita L McVicker; Kusum K Kharbanda; Dean J Tuma; Natalia A Osna
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-04-07       Impact factor: 4.052

3.  The hepatitis C virus core protein contains a BH3 domain that regulates apoptosis through specific interaction with human Mcl-1.

Authors:  Nur Khairiah Mohd-Ismail; Lin Deng; Sunil Kumar Sukumaran; Victor C Yu; Hak Hotta; Yee-Joo Tan
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

Review 4.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 5.  Management of alcohol misuse in patients with liver diseases.

Authors:  Jennifer L Peng; Milan Prakash Patel; Breann McGee; Tiebing Liang; Kristina Chandler; Sucharat Tayarachakul; Sean O'Connor; Suthat Liangpunsakul
Journal:  J Investig Med       Date:  2016-12-09       Impact factor: 2.895

6.  Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma.

Authors:  Azza E I El Bassiouny; Nora E I El-Bassiouni; Mona M F Nosseir; Mona M K Zoheiry; Eman G El-Ahwany; Faten Salah; Zeinab S O Omran; Raafat A Ibrahim
Journal:  Medscape J Med       Date:  2008-06-03

Review 7.  Production and pathogenicity of hepatitis C virus core gene products.

Authors:  Hui-Chun Li; Hsin-Chieh Ma; Chee-Hing Yang; Shih-Yen Lo
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 8.  Caspase inhibitors for the treatment of hepatitis C.

Authors:  Howard C Masuoka; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Clin Liver Dis       Date:  2009-08       Impact factor: 6.126

9.  HIV induces TRAIL sensitivity in hepatocytes.

Authors:  Challagundla K Babu; Kanitta Suwansrinon; Gary D Bren; Andrew D Badley; Stacey A Rizza
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

10.  Cysteine protease activation and apoptosis in Murine norovirus infection.

Authors:  Linnzi M Furman; Walid S Maaty; Lena K Petersen; Khalil Ettayebi; Michele E Hardy; Brian Bothner
Journal:  Virol J       Date:  2009-09-10       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.